Hantz Financial Services’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $0 | Hold |
29
| – | – | ﹤0.01% | 2254 |
|
|
2025
Q1 | $0 | Hold |
29
| – | – | ﹤0.01% | 1859 |
|
|
2024
Q4 | $0 | Hold |
29
| – | – | ﹤0.01% | 1166 |
|
|
2024
Q3 | $0 | Hold |
29
| – | – | ﹤0.01% | 1142 |
|
|
2024
Q2 | $0 | Hold |
29
| – | – | ﹤0.01% | 1184 |
|
|
2024
Q1 | $0 | Hold |
29
| – | – | ﹤0.01% | 1257 |
|
|
2023
Q4 | $0 | Hold |
29
| – | – | ﹤0.01% | 1187 |
|
|
2023
Q3 | $0 | Hold |
29
| – | – | ﹤0.01% | 1157 |
|
|
2023
Q2 | $0 | Hold |
29
| – | – | ﹤0.01% | 1137 |
|
|
2023
Q1 | $0 | Hold |
29
| – | – | ﹤0.01% | 1164 |
|
|
2022
Q4 | $0 | Hold |
29
| – | – | ﹤0.01% | 1124 |
|
|
2022
Q3 | $0 | Hold |
29
| – | – | ﹤0.01% | 1112 |
|
|
2022
Q2 | $0 | Hold |
29
| – | – | ﹤0.01% | 1081 |
|
|
2022
Q1 | $0 | Buy |
+29
| New | – | ﹤0.01% | 1085 |
|